{"name":"Rebiotix Inc.","slug":"rebiotix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RBX2660","genericName":"RBX2660","slug":"rbx2660","indication":"Recurrent Clostridioides difficile infection (rCDI)","status":"phase_3"},{"name":"Standard of Care Antibiotics","genericName":"Standard of Care Antibiotics","slug":"standard-of-care-antibiotics","indication":"Community-acquired pneumonia","status":"phase_3"}]}],"pipeline":[{"name":"RBX2660","genericName":"RBX2660","slug":"rbx2660","phase":"phase_3","mechanism":"RBX2660 is a microbiota restoration therapy that repopulates the gut microbiome to treat recurrent Clostridioides difficile infection.","indications":["Recurrent Clostridioides difficile infection (rCDI)"],"catalyst":""},{"name":"Standard of Care Antibiotics","genericName":"Standard of Care Antibiotics","slug":"standard-of-care-antibiotics","phase":"phase_3","mechanism":"Standard of care antibiotics work by inhibiting bacterial cell wall synthesis or interfering with protein synthesis.","indications":["Community-acquired pneumonia","Skin and soft tissue infections","Urinary tract infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9MWkt6RHdabWN3em9RRnY1bHpiVDg4RllsbVZhXzBfZkE2VkpxWlpBQWJBSDdQTGl6aUE3UFBydmY1RGh5Q3doblItUFJoWk9aQ0hFNDh5UTlvWHItejRVM1hGaml0cVplaHlmVFVfMUVTQUtfM0xaTTVn?oc=5","date":"2024-10-30","type":"pipeline","source":"Straits Research","summary":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033 - Straits Research","headline":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPcnFucUZkR3F0THNIbTZSaVlFQWd3b21jdjdvRENkYjJjNS1TbF9xWXVPZUVyZEF3Mlp3UW1udTZGckdIYmJNSDZkdDl5blZwX1FCYUhlM2k0bTdiTEwxa0xGS1FpM09SdmNXdEU0c0VhUVd4c0lYVjVVV3Y5MGN6SXVkMTMwNzZMdVU5VEFBTUplaENHN243dUdHM0JBd1p6QkFtNEg2cWRJOUFW?oc=5","date":"2023-11-22","type":"pipeline","source":"CBS News","summary":"Roseville biopharmaceutical company offers money for stool donations - CBS News","headline":"Roseville biopharmaceutical company offers money for stool donations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNNkdXSlFTRXZKUDZkUlgyNkN5cVRTNlBfR0N0N0c5VGx1TE5PcV94bWdVWnVORWU5bWFxd3BRQi0zQ2ZKSExVaGtuSkZocVBVS3JYRmVQTXQ5WUJyYUZtRGJHV2x1SHl6UWVXdFlEMkpSZFVIQVg1ZmtUZTlFaE1zbUNBd0NZVlI3Ujk1ZEdTQUZoSVVaTk5lNkRlWkVMc3U1WURmVdIBXkFVX3lxTFBaX2pGaG1JZjZWWWhVMGlPeW5md21vR1Zfc2VUMko4eGlNbWlqNHFDYm5oSVcxOW9tLWpmUm9mQXI0TTI5M1ZCWTVHamtwR3drTUxUaVRSdV96dENFSkE?oc=5","date":"2023-07-06","type":"pipeline","source":"Law360","summary":"Why One Company Placed Its Fate In Hands Of An IP Lawyer - Law360","headline":"Why One Company Placed Its Fate In Hands Of An IP Lawyer - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sZTJDMlBBbW9ST2kza3hSQktSckhrNkI4OVZyRzZ6NG5aZTlRbF9Sa2RDMEpfMzR1ankyTGhoU3k3ZEdGV3M1b081VWN6Q0Rpa3pXYkxON2Vmcmx2RlphZmFubmhqRnZ3?oc=5","date":"2022-12-22","type":"pipeline","source":"Labiotech.eu","summary":"10 biotech companies to watch in 2023 - Labiotech.eu","headline":"10 biotech companies to watch in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPbzB1aS1yd3ZQZmttc2FRUmZwSmc2aXA3LU1JUVR0RGdyUGtBLUxOOHAxU1M1SFZiZENDY01hYjdVcE9TZS1FVDlRSkR0RXpxR2pjMUQxWmJ5bklJRUNtZVhGU2NYYW94MFUwOWtCejh3NDR5bFpmZVBPNkJ3b1lZVWxLeXJJRWNoTmh4MFMzZHp4MHprY1hLdThmU0VUVzJFN3I1bGJPelRsamVkR2gzZGlWWTlJOFhqTEFsbmZFUFJvQWtlSmRIYjJ3OHg?oc=5","date":"2022-09-22","type":"regulatory","source":"Business Wire","summary":"Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660 - Business Wire","headline":"Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxONmVXOERRNWlvYVpxQVZ4LXNfdERTMENpQkdDRjBSSnZiNmFONkptLVFfSXFIQUY4dV9lR1pqM0s0U2ZubC1KOHlyNkhJUFY4VVBxb2ZWUmJHZkZPMDNVMmU3VUt3aG9OMWFfeDZvZVpWeW42TUNGVVNJZFFteEluT3RPS1hobE90WVF6ZEFhNFZDWU9fdWZjdkhUT3lMbHBYOTRBWGpjcUM4Y21ZNDRqRGU2TGJ2c2tTYmN2TVVITmlUTVZMLVFLUHFRYk1kakxpS0pfT2huN1doRVlXZ3JWTk1hVC00a01LUzRtaDRmTm9zUGEtQklVbnFaOXpEOTJYSWkzLXRxcmZtdzZpeHc?oc=5","date":"2021-10-25","type":"pipeline","source":"Business Wire India","summary":"Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021 - Business Wire India","headline":"Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1OV0tBTzFJWU05ZHM1Y3o1SGcxaVVrQUVLbTIybnRWRHdIaUFnaEIzLTREUnU4NXdMZ2FOMUFvc25oaEFiUGpYTHUzOTdQRm0wX3llakZsbGZ3eTJOVkE?oc=5","date":"2019-01-01","type":"pipeline","source":"Market.us","summary":"Human Microbiome Market Size, Share, Price | CAGR of 27.1% - Market.us","headline":"Human Microbiome Market Size, Share, Price | CAGR of 27.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9DcWxLOTA4YTJyT1RrNkxONG45blpQaldCelhqREdmSFE4VGZqVTlyUV83YU9ERVJnb1huMTREOHhZYkl1R1BrSk9vUnNwenBERzRzWkZJR1EwSGJDRHBoXzJzcDNVOEswbnpXYUFhQjBEQXEwSkNj?oc=5","date":"2018-05-23","type":"pipeline","source":"CTech","summary":"At Swiss Pharma Company, Women’s Health Gets Personal - CTech","headline":"At Swiss Pharma Company, Women’s Health Gets Personal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPNEJEX0V4a25Ud0dOTnZ2WHlCX2licWJYb2kxUWd3Y25lUzRMR2dlcU5scEZxTGlUMXdyam1nZE9QUFZTSmRCaGctdGNSQjMxMk5HRXc5LTltRk1rbUpRNTE3VkZWQUVyNU1lbTM2RnlaVk1KSk5uSHZnN2MzYTBLdExVYkxWdkNRT1o4YjFkM0NKQjR4M1N5NQ?oc=5","date":"2018-04-05","type":"deal","source":"Fierce Biotech","summary":"Ferring Pharma snags a microbiome platform with Rebiotix buy - Fierce Biotech","headline":"Ferring Pharma snags a microbiome platform with Rebiotix buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQSHBUX2NxNHN6N1h5eHNJZDl0WUp4dVNOTXpnNThESmI2TF9IaDJZM1RJdVh6V295bGNOZTUwMTEybHlQTkplM0hWcGNBWUV5YWVZcHh6aFhxZ1BnU1IxcmVRV0c2ZDdTT2xlaFk2RktyR09MZ1RYS2pkd2ticGoybmRpVlJTdw?oc=5","date":"2017-04-13","type":"pipeline","source":"pharmaphorum","summary":"Rebiotix microbiome drug success against C diff infection - pharmaphorum","headline":"Rebiotix microbiome drug success against C diff infection","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}